25 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) and a shorter life Ozempic for weight loss could

Clinician-recommended approaches prioritize reducing gastric load, avoiding triggers, and maintaining hydration while preserving nutritional intake

4 The study found that women receiving GLP-1s were 72% more likely to achieve natural pregnancy compared to those in control groups through three perceived reasons: direct weight loss, the role of GLP-1s on regulating the expression of certain steroid hormones, and through the reduction of inflammation, though more research is required to ascertain these benefits

Participants who took semaglutide were not more likely than those who received placebo to fully abstain from alcohol, and most participants did not have abstinence as a goal

J Pediatr 1983;102:931-5